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Abstract 
The use of big data containing millions of primary care medical records provides an opportunity for rapid 
research to help inform patient care and policy decisions during the first and subsequent waves of the 
COVID-19 pandemic. Routinely collected UK primary care data have previously been used for national 
pandemic surveillance, quantifying associations between exposures and outcomes, identifying high-
risk populations and examining the effects of interventions at scale. However, there is no consensus on 
how to effectively conduct or report these data for COVID-19 research. A COVID-19 primary care 
database consortium was established in April 2020. Collectively, its researchers have ongoing COVID-
19 projects in overlapping datasets with millions of primary care records representing 30% of the UK 
population, that are variously linked to public health, secondary care and vital status records. This 
consensus agreement is aimed at facilitating transparency and rigour in methodological approaches, 
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as well as consistency in defining and reporting cases, exposures, confounders, stratification variables 
and outcomes in relation to the pharmacoepidemiology of COVID-19. This will facilitate comparison, 
validation and pooling of research during and after the pandemic.  
Aim and scope 
Primary care ‘big data’ refers to routinely collected anonymised GP records that form large and complex 
longitudinal data, often with hundreds of variables at an individual level. These can often be linked to 
secondary care records, registry data (e.g. cancer) or the Office for National Statistics which records 
births and deaths.[1–3] A summary of the databases being utilised by our consortium is shown in table 
1 below. It is likely that additional data sources will be forthcoming and we would welcome these 
notifications. The potential use of primary care and linked data for understanding COVID-19 infection is 
vast, and includes descriptive epidemiology; testing associations with prescribed drugs, including drugs 
that influence risk; clinical prediction tools for COVID-19 risk and outcome; the impact on, and effects 
of’ health inequalities; or examining the indirect immediate and long-term effects of the infection, such 
as delayed clinical diagnoses, domestic abuse or mental health sequelae. Our present focus is on the 
pharmacoepidemiology of COVID-19, i.e. the potential influence of old and new drug therapies on 
COVID-19 outcomes. With an increasing number of studies using primary care big data to examine the 
influence of drugs on COVID-19 outcomes, it is timely to consider approaches to the conduct of these 
studies. This will facilitate study consistency and rigour, improve transparency and reduce ambiguity in 
both methods and reporting. As the pandemic progresses alongside the urgency to find solutions, rapid 
and rigorous research needs to be conducted with emergent findings externally validated. Consensus 
on definitions of COVID-19, exposures, outcomes, and consistency in considering potential 
confounders and stratification variables, will enable meaningful comparisons between findings and 
facilitate the potential for pooling results in meta-analyses. Our collective efforts and agreement on 
transparency in reporting and methodological approaches may contribute towards improved clinical 
decisions and in turn, improved population health. 
 
Table 1: Summary of database characteristics (for more information see relevant websites) 
 QResearch RCGP Research 
& Surveillance 





Established 2003 1957 1989 2006 
Number of GP Practices  1500  
(increasing 
to 2519 from 
April 2020) 
700 1841 Partial 
cohort 
coverage 
Number of current patient 
records as of 01.01.2020 
10.6 million 
(rising to 21 
million from 
April 2020) 
5 million 14 million 0.5 million 
Coverage England England All of UK England, 
Wales and 
Scotland 
Age groups All  All  All  40-69 years 
at 
recruitment 
Clinical system EMIS EMIS Web, INPS 
Vision, TPP 
System One 




Birth registration Yes Yes Yes No 
Death registration Yes Yes Yes Yes 
Sociodemographic data Yes Yes Yes Yes 
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Ethnicity Yes Yes Yes Yes 
Genome-wide genotyping 
data  
No No No Yes 
Geographical location Yes Yes Yes Yes 
Laboratory tests including 
COVID-19 results 
Yes Yes Yes Yes 
Anthropometric data Yes Yes Yes Yes 
Clinical signs and 
symptoms 
Yes Yes Yes Yes 
Drugs prescribed Yes Yes Yes Yes 
Radiology reports Yes Yes Yes  No 
Hospital referral Yes Yes Yes Yes 
Hospital diagnosis Yes Yes Yes Yes 
GP attendances Yes Yes Yes Partial 
Hospital attendance Yes Yes Yes Yes 
Additional key linkages to 
other datasets 
(full lists available from 




Yes Yes Yes No 
HES outpatient 
data  
Yes Yes Yes No 
HES accident and 
emergency data 
Yes Yes Yes No 
HES diagnostic 
imaging dataset 
Yes Yes Yes No 
Death registration 
data from the 
Office for National 
Statistics 






Yes No Pending No 
Further information, 













Development of the consensus statement 
This statement was developed by our primary care database consortium which includes UK experts in 
big data, epidemiologists, researchers in intensive care, researchers in primary care, statisticians, 
patient and public representatives, editors for journals in the field and front-line clinical staff. Universities 
represented are Bristol, Cambridge, Manchester, Nottingham, Oxford and Southampton. After initial 
discussions on the need for such a statement in our respective projects, we met weekly to refine ideas 
and reach agreement on item inclusion. The recommendations are entirely those of the consortium with 
sponsors and funders having no role in their development or reporting. 
Agreed items for inclusion 
1. Protocols 
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Wherever possible, protocols and analysis plans for COVID-19 research using primary care big data 
will be made widely available as quickly as possible through open-access journals or publicly available 
institutional repositories ahead of commencing the data analysis. This will facilitate transparency and 
subsequent scrutiny of findings, and a priori analysis plans should reduce false positive findings. Given 
the urgency of the research during the current pandemic, this will encourage greater efficiency and less 
duplication of efforts, unless conducted for validation purposes.  
 
2. Defining COVID-19 infection 
We considered the World Health Organization and Public Health England definitions of COVID-19 
infection (as of 13th March 2020). [4,5] These definitions have several limitations in terms of 
operationalising them within database of electronic medical records. For example, clinical symptoms 
such as nasal discharge or sneezing may not necessarily be coded within GP records. Virology and 
serology tests that are being used to define cases are still being validated with varying reports on 
sensitivity and specificity.[6] UK national testing has been sparse, and has varied between the hospital 
and community setting at different stages of the pandemic. Definitions are likely to change and develop 
over time as more standardisation of GP coding is introduced, testing rates are widened from largely 
secondary to community settings and more accurate tests of infection and immunity are developed. 





Positive result on RT-PCR assay of nasal or pharyngeal swab specimen ever 
OR 





From 20th January 2020 (date that first confirmed case outside mainland China 




1.Requiring admission to hospital   
 
AND one or more of the following: 
 
Clinical evidence of pneumonia  
OR 
Radiological evidence of pneumonia  
OR 
Acute respiratory distress syndrome  
OR 
Influenza like illness (fever ≥37.8°C and at least one of 
the following respiratory symptoms, which must be of 
acute onset: persistent cough (with or without sputum), 
hoarseness, nasal discharge or congestion, shortness 
of breath, sore throat, wheezing, sneezing  
 
   
 
This article is a preprint and has not been peer reviewed. It reports new medical research or thought that has yet to be evaluated 
and so should not be used to guide clinical practice. Copyright ©2020 by Hajira Dambha-Miller MRCGP PhD FHEA.  
Posted on Annals of Family Medicine COVID-19 Collection, courtesy of Hajira Dambha-Miller. 
  
 
OR 2.Not admitted to hospital 
 
AND one or more of the following: 
 





with a negative test 
 
Negative result (never positive) on RT-PCR assay of nasal or pharyngeal swab 
specimen  
OR 




3. Drug exposures 
Where prescribed drugs are being examined in COVID-19 infection, the following reporting principles 
should be applied:  
Report generic drug name 
 
List distinct classes of drugs (e.g. Angiotensin Receptor Blockers and Angiotensin-Converting 




Provide individual drug names 
Where combination preparations have been prescribed, consider the component ingredients as 
separate for the purposes of the analysis 
 
Provide clear definitions of drug exposure including:  
i. Exposure time – describe relevant dates of prescription for drug being investigated in 
relation to COVID-19 case-definition date; i.e. time duration before/during/after 
infection. For research questions with specific aim of altering outcomes, drug exposure 
during/after infection will be most informative 
ii. Repeat prescriptions for long term medication – list number of prescriptions within a 
defined time period 
iii. Dosage – describe how different drug dosage regimens are being treated in analysis 
 
 
A list of UK prescribed drugs that require urgent characterisation for their potential in treating or altering 
outcomes in COVID-19 is given in the supplementary material 1. This list was compiled from the limited 
existing literature on this subject, our ongoing systematic review and anecdotal evidence from front line 
clinical staff who are treating patients with COVID-19 infections. [7–11] It is not an exhaustive list and 
will be updated as more data become available. Drug names within classes have been extracted from 
the British National Formulary.  
4. Confounding variables 
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A list of variables that we recommend reporting and considering for inclusion as confounders within 
statistical models can be found in the supplementary material 2. We have not provided restrictive 
recommendations on how these variables should be categorised as this is dependent on the data 
available and the individual discretion of the researcher. We suggest consideration of these variables 
when determining confounders alongside a clear description of how the categorisation of the variable 
was determined and the rationale for its inclusion.  
 
5. Stratification variables 
In response to emergent findings on particular subgroups within the population being disproportionally 
affected by COVID-19 infection, [12] we propose examining outcomes stratified by age, sex, ethnic 
group and domicile (own home vs care/nursing home). As more data are published, further stratification 
variables should be considered. 
6. Outcome reporting 
We endorse the use of an appropriate reporting guideline such as the STROBE, RECORD or 
TRIPOD checklist. [13–15] We have considered outcomes from both ICU and primary care data as 
some linked datasets are being used within our consortium. Wherever possible, the following data 
should be reported: 
Primary care 
outcomes 
Short term Lower Respiratory Tract Infection (Pneumonia) 
Emergency admission  
ICU admission 






Vital status at ICU discharge (alive/dead) 
Vital status at acute hospital discharge (alive/dead) 
Days of advanced respiratory support (artificial ventilation) 
Days of advanced cardiovascular support (inotropes, pressors 
or mechanical cardiovascular support) 
Days of renal support (use of renal replacement therapy) 
Days of ICU care (reported as ICU admission to discharge) 
Days of acute hospital care after ICU discharge (for repeat ICU 
admissions in the same acute hospital admission the total days 
not on ICU should be used)  
Long term Vital status (alive/dead) at 30 and 90 days after ICU admission 
All-cause and COVID-related specific mortality at 6 and 12 
months after ICU admission 
 
 
7. Analytical methods 
Individual study analyses are likely to vary from project to project. We agree on the ensuring analytical 
methods are transparent and reported in full, with the following guiding principles; 
 
State an a priori hypothesis 
 
Report descriptive characteristics including age, sex, ethnic group, measures of deprivation (such 
as the IMD or Townsend deprivation score), comorbidities and medication use 
 
State sample size considerations, power calculations , and multiple testing considerations 
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Consider clustering by ICU or general practices or physician and employ appropriate methods e.g. 
robust standard errors 
 
Check assumptions for any models (e.g. proportional hazards assumption) 
 
Report how missing data were managed (e.g. multiple imputation method to replace missing data) 
 
Report both unadjusted and adjusted models  
 
Report any methods used to examine subgroups and interactions 
 
Report on causal analysis methods, e.g. instrumental variables analysis [16] 
 
Report any sensitivity analyses 
 
Report on steps taken to mitigate time-window bias (in case-control study designs) or immortal time 
bias (in cohort study designs) [17] 
 
 
Key challenges and shortcomings in the use of primary care big data for COVID-19 research 
Across the respective primary care datasets, we acknowledge the potential limitations of using big data 
for COVID-19 research. All data are collected from routine clinical care. They are dependent on 
accurate coding by individual clinicians, and this does not guarantee consistency or accuracy of codes. 
Data on exposures and confounders will have been entered before the pandemic, and there might be 
a delay in outcome data reaching GP records. Uptake of newly introduced codes that are specific to 
COVID-19 may not be universal. Historically, however, UK primary care records have always been of 
a high level in terms of accuracy, and completeness of clinical diagnosis and medication prescribing. 
[18,19] The use of non-randomised observational data to make causal inferences still requires careful 
interpretation and appropriate analyses.[20] Other considerations relate to the case definition of COVID-
19. Our definitions have been informed by those proposed by Public Health England and the WHO. We 
will utilise positive RT-PCR or serology testing as a definitive way of confirming cases.  UK testing for 
COVID-19 has been limited and to date, we are not aware of any established serology or virology test 
with high sensitivity or specificity. Moreover, recent modelling suggests that there might be a substantial 
proportion of asymptomatic COVID-19 cases. [21] These individuals will not have presented to the 
health services and will not be identified within our datasets.   
It is plausible that big data will over-represents disease severity and the factors contributing towards it 
because these less severe and asymptomatic cases are not recorded. This will be less relevant in 
subgroup designs or analyses assessing the risk of adverse outcomes in those presenting to hospital 
or ICU. All observational studies nested within these databases will be subject to the usual risk of 
statistical error (type 1 or type 2), bias and confounding. These must be considered in terms of size and 
direction. It is likely that many of the biases will be non-differential and minimised to some extent by the 
large sample sizes afforded by the data. Moreover, these primary care data lack selection and recall 
biases and often include multiple linkages to enable best-attainable ascertainment of outcome and 
exposure data. Large sample sizes will increase precision but could also lead to false positives. In the 
early stages, the number of people with outcomes recorded in GP records will be small but this is rising 
rapidly and the timing of analyses will therefore be important. If conducted too early the sample size will 
be inadequate but if too late, opportunities for findings to influence policy will be missed.  
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Angiotensin Converting Enzyme-Inhibitors including: 
Captopril 
Enalapril maleate 




Lisinopril with hydrochlorothiazide 
Perindopril arginine 
Perindopril arginine with indapamide 
Perindopril erbumine 
Quinapril 
Quinapril with hydrochlorothiazide 
Ramipril 
Ramipril with felodipine 
Trandolapril 
 
Angiotensin Receptor Blocker and combinations including: 





Irbesartan with hydrochlorothiazide 
Losartan potassium 
Losartan with hydrochlorothiazide 
Olmesartan medoxomil 
Olmesartan with amlodipine 
Olmesartan with amlodipine and hydrochlorothiazide 
Olmesartan with hydrochlorothiazide 
Sacubitril with valsartan 
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Telmisartan with hydrochlorothiazide 
Valsartan 




Non-steroidal Anti-inflammatory Drugs including: 
Aceclofenac 
Aspirin 
Aspirin with codeine 
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Thiazolidinediones and their combinations including: 
Pioglitazone with metformin 
Pioglitazone 
 
Metformin and its combinations including: 
Alogliptin with metformin 
Canagliflozin with metformin 
Dapagliflozin with metformin 
Empagliflozin with metformin 
Linagliptin with metformin 
Metformin hydrochloride 
Saxagliptin with metformin 
Sitagliptin with metformin 













Insulin degludec with liraglutide 
Insulin detemir 
Insulin glargine 
Insulin glargine with lixisenatide 
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Protamine zinc insulin 
Biphasic isophane insulin 
Biphasic insulin aspart 





Sodium glucose co-transporter 2 inhibitors and combinations including: 
Canagliflozin 
Canagliflozin with metformin 
Dapagliflozin 
Dapagliflozin with metformin 
Empagliflozin 
Empagliflozin with linagliptin 
Empagliflozin with metformin 
Ertugliflozin 
Saxagliptin with dapagliflozin 
 
Gliptans and its combinations including: 
Alogliptin 
Alogliptin with metformin 
Empagliflozin with linagliptin 
Linagliptin 
Linagliptin with metformin 
Saxagliptin 
Saxagliptin with dapagliflozin 
Saxagliptin with metformin 
Sitagliptin 
Sitagliptin with metformin 
Vildagliptin 
Vildagliptin with metformin 
 
Glucagon-like peptide-1 receptor agonists and combinations including: 
Dulaglutide 
Exenatide 
Insulin glargine with lixisenatide 
Liraglutide 
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Protease inhibitors including: 
Atazanavir 
Atazanavir with cobicistat 
Darunavir 
Darunavir with cobicistat 
Darunavir with cobicistat, emtricitabine and tenofovir alafenamide  
Fosamprenavir 
Lopinavir with ritonavir 



















Inhaled and nasal steroids including: 
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Beclometasone with formoterol 
Beclometasone with formoterol and glycopyrronium 
Betamethasone 
Budesonide 
Budesonide with formoterol 
Ciclesonide 
Fluticasone with azelastine 
Fluticasone with formoterol 
Fluticasone with salmeterol 
Fluticasone with umeclidinium and vilanterol 
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Proton pump inhibitors including: 
Esomeprazole 
Lansoprazole 










Simvastatin with ezetimibe  













Oral anticoagulants including: 
Acenocoumarol 
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Calcium channel blockers including: 
Amlodipine  
Amlodipine with valsartan  
Atenolol with nifedipine  
Diltiazem hydrochloride  
Felodipine  
Lacidipine  
Lercanidipine hydrochloride  
Nicardipine hydrochloride  
Nifedipine  
Olmesartan with amlodipine  
Olmesartan with amlodipine and hydrochlorothiazide  
Ramipril with felodipine  
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Chronic Liver Disease 
 











Social care variables: 




Care Home/Nursing Home Resident 
 
Poor mobility bed ridden or housebound 
 
 
 
